Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Hall 4EF
Objective To investigate the outcomes of transplanting kidneys from HBsAg positive donors to HBsAb positive recipients.
Methods We retrospectively collected data of 57 kidney transplants from HBsAg positive donors to HBsAb positive recipients from January 2005 to December 2014. If HBsAb titer of recipient was between 100IU to 1000 IU, the recipient received anti-HBV immunoglobulin for two weeks and lamivudine or entecavir for 1 months in order to prevent HBV infection. If HBsAb titer of recipient was more than 1000IU, they only received lamivudine or entecavir for two weeks. HBV DNA was monitored every week in the first month and then every 1 month within 1 year.
Results No HBV infection was seen in these 57 recipients. No HBV DNA detected in these recipients after kidney transplantation. 5 recipients had hepatic function impairment, which might be caused by the side effects of immunosuppressive drugs.
Conclusion Kidney transplantation from HBsAg positive donors to HBsAb positive recipients is safe if given appropriate prophylactic anti-HBV treatment.
CITATION INFORMATION: Chen G., Wang C., Wu Z., Liu X., Wang C., Chen L. Outcomes of Kidney Transplantation from HBsAg Positive Donors to HBsAb Positive Recipients Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:Chen G, Wang C, Wu Z, Liu X, Wang C, Chen L. Outcomes of Kidney Transplantation from HBsAg Positive Donors to HBsAb Positive Recipients [abstract]. https://atcmeetingabstracts.com/abstract/outcomes-of-kidney-transplantation-from-hbsag-positive-donors-to-hbsab-positive-recipients/. Accessed April 7, 2020.
« Back to 2018 American Transplant Congress